JP2024534824A5 - - Google Patents

Info

Publication number
JP2024534824A5
JP2024534824A5 JP2024511978A JP2024511978A JP2024534824A5 JP 2024534824 A5 JP2024534824 A5 JP 2024534824A5 JP 2024511978 A JP2024511978 A JP 2024511978A JP 2024511978 A JP2024511978 A JP 2024511978A JP 2024534824 A5 JP2024534824 A5 JP 2024534824A5
Authority
JP
Japan
Prior art keywords
sequence
seq
polypeptide
identity
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024511978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534824A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/041471 external-priority patent/WO2023038803A2/en
Publication of JP2024534824A publication Critical patent/JP2024534824A/ja
Publication of JP2024534824A5 publication Critical patent/JP2024534824A5/ja
Pending legal-status Critical Current

Links

JP2024511978A 2021-08-25 2022-08-25 操作された抗ｈｅｒ２二重特異性タンパク質 Pending JP2024534824A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163237071P 2021-08-25 2021-08-25
US63/237,071 2021-08-25
PCT/US2022/041471 WO2023038803A2 (en) 2021-08-25 2022-08-25 Engineered anti-her2 bispecific proteins

Publications (2)

Publication Number Publication Date
JP2024534824A JP2024534824A (ja) 2024-09-26
JP2024534824A5 true JP2024534824A5 (cg-RX-API-DMAC7.html) 2025-08-28

Family

ID=85506758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024511978A Pending JP2024534824A (ja) 2021-08-25 2022-08-25 操作された抗ｈｅｒ２二重特異性タンパク質

Country Status (5)

Country Link
US (1) US20240392035A1 (cg-RX-API-DMAC7.html)
EP (1) EP4392064A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534824A (cg-RX-API-DMAC7.html)
CN (1) CN118119402A (cg-RX-API-DMAC7.html)
WO (1) WO2023038803A2 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010166A (es) * 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
AU2014357292B2 (en) * 2013-11-27 2020-06-25 Zymeworks Bc Inc. Bispecific antigen-binding constructs targeting HER2
EP3083696B1 (en) * 2013-12-20 2018-02-14 F.Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
WO2020037150A2 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
JP2021534220A (ja) * 2018-08-22 2021-12-09 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法
AU2021224200A1 (en) * 2020-02-19 2022-09-08 Denali Therapeutics Inc. Engineered anti-HER2 bispecific proteins

Similar Documents

Publication Publication Date Title
JP2021533779A5 (cg-RX-API-DMAC7.html)
JP2022518925A5 (cg-RX-API-DMAC7.html)
JP2023548443A5 (cg-RX-API-DMAC7.html)
JP2023514371A5 (cg-RX-API-DMAC7.html)
JP2021534762A5 (cg-RX-API-DMAC7.html)
JP2019502712A5 (cg-RX-API-DMAC7.html)
ES2334895T3 (es) Mini-anticuerpo humano citotoxico para las celulas tumorales que expresan el receptor erbb2.
JP2023181445A5 (cg-RX-API-DMAC7.html)
JP2021522162A5 (cg-RX-API-DMAC7.html)
JP2021159081A5 (cg-RX-API-DMAC7.html)
KR20140067944A (ko) 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
JP2024532485A5 (cg-RX-API-DMAC7.html)
JP2021534220A5 (cg-RX-API-DMAC7.html)
JP2013515508A5 (cg-RX-API-DMAC7.html)
JP2022512043A5 (cg-RX-API-DMAC7.html)
JP2018504092A5 (cg-RX-API-DMAC7.html)
EP2964676A1 (en) Anti-c-met tandem fc bispecific antibodies
JP2024501403A5 (cg-RX-API-DMAC7.html)
JP2023532807A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2021521781A5 (cg-RX-API-DMAC7.html)
JP2023506834A5 (cg-RX-API-DMAC7.html)
CA3170338A1 (en) Engineered anti-her2 bispecific proteins
JP2023545707A5 (cg-RX-API-DMAC7.html)
JP2025508867A5 (cg-RX-API-DMAC7.html)